Related references
Note: Only part of the references are listed.Stability of Alemtuzumab for Low-Dose Induction and Test Doses
L. C. Vermuelen et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia
Claes Karlsson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Rediscovering alemtuzumab: current and emerging therapeutic roles
John G. Gribben et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
New prognostic markers in chronic lymphocytic leukemia
Carol Moreno et al.
BLOOD REVIEWS (2008)
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
John D. Hainsworth et al.
CANCER (2008)
Pharmacokinetics of alemtuzumab and the relevance in clinical practice
Thomas Elter et al.
LEUKEMIA & LYMPHOMA (2008)
Antibody therapy for chronic lymphocytic leukemia
Beth A. Christian et al.
SEMINARS IN HEMATOLOGY (2008)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia
L. Alinari et al.
ONCOGENE (2007)
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath (R)) in patients with chronic lymphocytic leukaemia and its link to treatment response
D. R. Mould et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia
M Montillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
G Lozanski et al.
BLOOD (2004)
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
G Hale et al.
BLOOD (2004)
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission -: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
CM Wendtner et al.
LEUKEMIA (2004)
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
J Lundin et al.
BLOOD (2002)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
